Kapitalo Investimentos Ltda Takes Position in West Pharmaceutical Services, Inc. (NYSE:WST)

Kapitalo Investimentos Ltda bought a new position in shares of West Pharmaceutical Services, Inc. (NYSE:WST) during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor bought 204 shares of the medical instruments supplier’s stock, valued at approximately $72,000.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Copperwynd Financial LLC lifted its position in shares of West Pharmaceutical Services by 4.0% during the fourth quarter. Copperwynd Financial LLC now owns 778 shares of the medical instruments supplier’s stock worth $274,000 after purchasing an additional 30 shares in the last quarter. Portside Wealth Group LLC boosted its position in West Pharmaceutical Services by 1.2% in the 4th quarter. Portside Wealth Group LLC now owns 2,675 shares of the medical instruments supplier’s stock valued at $942,000 after buying an additional 33 shares during the period. Peninsula Asset Management Inc. grew its stake in shares of West Pharmaceutical Services by 0.4% in the fourth quarter. Peninsula Asset Management Inc. now owns 9,580 shares of the medical instruments supplier’s stock worth $3,373,000 after acquiring an additional 35 shares in the last quarter. Addison Advisors LLC increased its position in shares of West Pharmaceutical Services by 28.9% during the fourth quarter. Addison Advisors LLC now owns 183 shares of the medical instruments supplier’s stock worth $64,000 after acquiring an additional 41 shares during the period. Finally, Raymond James Trust N.A. raised its stake in shares of West Pharmaceutical Services by 1.6% in the fourth quarter. Raymond James Trust N.A. now owns 2,869 shares of the medical instruments supplier’s stock valued at $1,010,000 after acquiring an additional 45 shares in the last quarter. 93.90% of the stock is currently owned by hedge funds and other institutional investors.

West Pharmaceutical Services Trading Up 2.0 %

WST opened at $328.47 on Friday. The business has a fifty day moving average price of $348.71 and a 200 day moving average price of $361.15. The company has a debt-to-equity ratio of 0.03, a current ratio of 2.61 and a quick ratio of 1.95. West Pharmaceutical Services, Inc. has a 12 month low of $310.00 and a 12 month high of $415.73. The stock has a market capitalization of $23.93 billion, a price-to-earnings ratio of 43.33, a PEG ratio of 5.69 and a beta of 1.01.

West Pharmaceutical Services (NYSE:WST) last announced its quarterly earnings data on Thursday, April 25th. The medical instruments supplier reported $1.56 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.29 by $0.27. West Pharmaceutical Services had a return on equity of 20.57% and a net margin of 19.42%. The business had revenue of $695.40 million during the quarter, compared to analysts’ expectations of $670.62 million. During the same quarter last year, the business posted $1.98 EPS. The business’s quarterly revenue was down 3.0% compared to the same quarter last year. Sell-side analysts expect that West Pharmaceutical Services, Inc. will post 7.76 earnings per share for the current fiscal year.

West Pharmaceutical Services Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, August 7th. Stockholders of record on Wednesday, July 31st will be issued a $0.20 dividend. The ex-dividend date is Wednesday, July 31st. This represents a $0.80 dividend on an annualized basis and a dividend yield of 0.24%. West Pharmaceutical Services’s payout ratio is 10.55%.

Insider Transactions at West Pharmaceutical Services

In related news, CEO Eric Mark Green sold 66,000 shares of the stock in a transaction on Tuesday, May 7th. The stock was sold at an average price of $366.65, for a total value of $24,198,900.00. Following the transaction, the chief executive officer now owns 152,908 shares of the company’s stock, valued at $56,063,718.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In other news, SVP Silji Abraham sold 1,800 shares of the business’s stock in a transaction that occurred on Wednesday, June 12th. The shares were sold at an average price of $330.78, for a total transaction of $595,404.00. Following the completion of the sale, the senior vice president now owns 2,860 shares in the company, valued at approximately $946,030.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Eric Mark Green sold 66,000 shares of the company’s stock in a transaction on Tuesday, May 7th. The shares were sold at an average price of $366.65, for a total transaction of $24,198,900.00. Following the completion of the transaction, the chief executive officer now owns 152,908 shares of the company’s stock, valued at approximately $56,063,718.20. The disclosure for this sale can be found here. Corporate insiders own 0.53% of the company’s stock.

West Pharmaceutical Services Company Profile

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.